5651-01-4

Basic information

• Product Name: Benzoic acid,2-[(carboxycarbonyl)amino]-
• Synonyms: Oxanilicacid, 2'-carboxy- (6CI,8CI); 2-(Oxalylamino)benzoic acid
• CAS NO: 5651-01-4
• Molecular Formula: C9H7 N O5
• Molecular Weight: 209.158
• Mol File: 5651-01-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid,2-[(carboxycarbonyl)amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid,2-[(carboxycarbonyl)amino]-(5651-01-4)
• EPA Substance Registry System: Benzoic acid,2-[(carboxycarbonyl)amino]-(5651-01-4)

Safety Data

• Hazardous Substances Data: 5651-01-4(Hazardous Substances Data)

Upstream product

• 529-37-3 4(1H)-quinolinone 
• 5332-24-1 3-bromoquinoline 
• 174575-83-8 2-(2-methoxy-2-oxoacetamido)benzoic acid 
• 2437-05-0 ethyl 3-(2-nitrophenyl)acrylate 
• 612-62-4 2-Chloroquinoline 
• 118-92-3 anthranilic acid 
• 485-47-2 indan-1,2,3-trione hydrate 
• 51679-85-7 2-carboxyoxanilic acid ethyl ester 
• 861609-06-5 N¹-(2-carboxyphenyl)-N²-phenyloxalamide 
• 492-27-3 kinurenic acid 
• 59-31-4 2-quinolone 
• 42712-64-1 2-amino-quinolin-4-ol 
• 4169-19-1 1-acetyl-1,2,3,4-tetrahydroquinoline 
• 64-19-7 acetic acid 

Downstream Products

• 144-62-7 oxalic acid 
• 118-92-3 anthranilic acid 
• 612-42-0 phenylglycine-o-carboxylic acid 
• 69065-89-0 methyl N-(2-methoxycarbonylphenyl)oxalamate 

Relevant articles and documents

Inhibitors of fumarylacetoacetate hydrolase domain containing protein 1 (Fahd1)

FAH domain containing protein 1 (FAHD1) acts as oxaloacetate decarboxylase in mitochondria, contributing to the regulation of the tricarboxylic acid cycle. Guided by a high-resolution X-ray structure of FAHD1 liganded by oxalate, the enzymatic mechanism of substrate processing is analyzed in detail. Taking the chemical features of the FAHD1 substrate oxaloacetate into account, the potential inhibitor structures are deduced. The synthesis of drug-like scaffolds afforded first-generation FAHD1-inhibitors with activities in the low micromolar IC50 range. The investigations disclosed structures competing with the substrate for binding to the metal cofactor, as well as scaffolds, which may have a novel binding mode to FAHD1.

Modulators of protein tyrosine phosphatases (PTPases)

The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, wherein A, R1, R2, R3, R4, R16and R17are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

SYNTHESES AND REACTION OF 2-CHLOROFORMYL 4H-3,1-BENZOXAZIN-4-ONE

-